thumbnail image

Jonathan W. Simons, MD, Prostate Cancer Foundation

 

news:: Drug Discovery in Academia
Back to Drug Discovery in Academia

Prostate Cancer Foundation

Jonathan W. Simons, MD
Jonathan W. Simons, MD, is President and Chief Executive Officer and David H. Koch Chair of the Prostate Cancer Foundation.  He is an internationally recognized physician-scientist, oncologist and acclaimed investigator in translational prostate cancer research. Prior to joining PCF in 2007, he was Distinguished Service Professor of Hematology and Oncology at the Emory University School of Medicine and Professor of Biomedical Engineering and Materials Sciences at the Georgia Institute of Technology. Dr. Simons is the Founding Director of the Winship Cancer Institute at Emory University in Atlanta and Co-Director of the National Cancer Institute Center for Cancer Nanotechnology Excellence at Emory and Georgia Tech.

Dr. Simons received a BA from Princeton University and an MD from The Johns Hopkins University School of Medicine. Before entering medical school he was a Rotary International Postgraduate Fellow in the Humanities at the University of Kent in Canterbury, England, and a Nuffield Foundation Fellow in the Department of Biochemistry at the University of Cambridge. Dr. Simons completed his residency in internal medicine at Massachusetts General Hospital at Harvard Medical School and his fellowship in medical oncology at Johns Hopkins. Dr. Simons has been a funded physician-scientist in prostate cancer by the National Cancer Institute, Department of Defense, PCF and other agencies since 1990. He is also board-certified in internal medicine and medical oncology. He is married to Plum Simons, a breast cancer survivor, and has two sons.

Prostate Cancer Foundation
Firmly committed to curing prostate cancer, the Prostate Cancer Foundation is the leading philanthropic organization funding and accelerating research globally.



Since 1993, our unique strategies for identifying and investing in the most promising research programs have generated life-saving results. We channel resources to the world’s top scientific minds—cutting red tape and encouraging collaboration to speed breakthroughs.

As a champion for increased government and private support, PCF has helped build a global research enterprise of nearly $10 billion. Through the generous contributions of our donors, we have funded more than 1,500 programs at nearly 200 research centers in 12 countries.

The Reliable Source for the Latest Developments:  For more than 16 million men and their families fighting prostate cancer globally, PCF is a primary source for new standard-of-care and research information. We connect patients, loved ones, care providers and scientists to critical updates, the latest developments, best practices and news from the treatment pipeline.


Advancing Hope, with Your Help:  Many important discoveries in the fight against prostate cancer since 1993 resulted from PCF funding or coordination—including the development of new medications, gene therapy approaches and the development of vaccines that may soon work with the body’s immune system to kill prostate cancer cells.

 
Share This Information